RESMED News & Analysis

Morningstar analyst Shane Ponraj discusses the latest clinical trial results from Eli Lilly.

Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.

Strong device sales and rebound in margin.

Despite advancing from its October low, the undervalued stock of this narrow-moat company may have more room to run.

Shares rose after strong earnings report but remain materially undervalued. 

Stock markets are highly efficient in the long run yet share prices can fluctuate wildly near term. The art of investing is buying quality stocks...

Analysts predict margin expansion on a materially undervalued stock. 

The potential for weight loss drugs to impact the sleep apnea giant has weighed on the share price, though Morningstar analyst Shane Ponraj thinks...

Our analyst believes the respiratory care provider is set to command the untapped sleep apnea industry as competitors struggle.

It may rank as one of Morningstar’s most overvalued sectors, but the safety of healthcare stocks can still provide value to investors—if...